文献速递胸部肿瘤

可切除非小细胞肺癌新辅助度伐利尤单抗单药或联合新型免疫肿瘤药物治疗:II期NeoCOAST平台试验

Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial.
PubMed 文献 · Cancer Discov · 2023-01-01

NeoCOAST是首个在可切除非小细胞肺癌患者中评估新型新辅助免疫联合方案的随机多药平台试验,以主要病理缓解率为主要终点。83例患者接受单周期治疗:度伐利尤单抗单药26例、联合oleclumab 21例、联合monalizumab 20例、联合danvatirsen 16例。联合组主要病理缓解率高于度伐利尤单抗单药组,安全性相似。

要点

  • 可切除非小细胞肺癌患者单周期新辅助度伐利尤单抗联合oleclumab或monalizumab的主要病理缓解率高于度伐利尤单抗单药。
  • 联合方案安全性特征与度伐利尤单抗单药相似。
  • 度伐利尤单抗联合oleclumab或monalizumab组主要病理缓解率提高与肿瘤效应免疫浸润增强、干扰素反应及三级淋巴结构形成标志物相关。

核心结论

  • 可切除非小细胞肺癌患者接受度伐利尤单抗联合oleclumab或monalizumab的新辅助治疗后主要病理缓解率高于度伐利尤单抗单药,且肿瘤转录组特征提示免疫细胞活化与功能增强。

研究设计与样本

  • NeoCOAST是首个随机、多药平台试验,评估可切除非小细胞肺癌患者的新型新辅助免疫肿瘤联合方案,以主要病理缓解率为主要终点。
  • 83例患者接受单周期治疗:度伐利尤单抗单药26例,度伐利尤单抗联合oleclumab 21例,度伐利尤单抗联合monalizumab 20例,度伐利尤单抗联合danvatirsen 16例。

主要发现

  • 联合治疗组的主要病理缓解率高于度伐利尤单抗单药组。
  • 联合方案的安全性特征与度伐利尤单抗单药相似。
  • 多重免疫分析提示,度伐利尤单抗联合oleclumab和度伐利尤单抗联合monalizumab组主要病理缓解率提高与肿瘤效应免疫浸润增强、干扰素反应及三级淋巴结构形成标志物以及全身功能性免疫细胞活化相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Neoadjuvant chemoimmunotherapy improves pathologic complete response rate and event-free survival in patients with resectable non-small cell lung cancer (NSCLC) versus chemotherapy alone. NeoCOAST was the first randomized, multidrug platform trial to examine novel neoadjuvant immuno-oncology combinations for patients with resectable NSCLC, using major pathologic response (MPR) rate as the primary endpoint. Eighty-three patients received a single cycle of treatment: 26 received durvalumab (anti-PD-L1) monotherapy, 21 received durvalumab plus oleclumab (anti-CD73), 20 received durvalumab plus monalizumab (anti-NKG2A), and 16 received durvalumab plus danvatirsen (anti-STAT3 antisense oligonucleotide). MPR rates were higher for patients in the combination arms versus durvalumab alone. Safety profiles for the combinations were similar to those of durvalumab alone. Multiplatform immune profiling suggested that improved MPR rates in the durvalumab plus oleclumab and durvalumab plus monalizumab arms were associated with enhanced effector immune infiltration of tumors, interferon responses and markers of tertiary lymphoid structure formation, and systemic functional immune cell activation. SIGNIFICANCE: A neoadjuvant platform trial can rapidly generate clinical and translational data using candidate surrogate endpoints like MPR. In NeoCOAST, patients with resectable NSCLC had improved MPR rates after durvalumab plus oleclumab or monalizumab versus durvalumab alone and tumoral transcriptomic signatures indicative of augmented immune cell activation and function. See related commentary by Cooper and Yu, p. 2306. This article is featured in Selected Articles from This Issue, p. 2293.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Cascone T, Kar G, Spicer JD, et al. Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial. Cancer Discov. 2023. PMID: 37707791. doi:10.1158/2159-8290.CD-23-0436

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。